Researchers used data from Kaiser Permanente of Northern California to retrospectively assess patients with type 2 diabetes who initiated a long-acting insulin analog or NPH insulin between Jan. 1, 2006, and Sept. 30, 2015.
Glucagon-like peptide-1 (GLP-1) agonists were associated with a higher risk of adverse events than sodium-glucose cotransporter-2 (SGLT2) inhibitors or dipeptidyl peptidase 4 (DPP-4) inhibitors, according to the meta-analysis.
Researchers examined asymptomatic patients 65 years of age and older with type 2 diabetes and preserved left ventricular ejection fraction to look for impaired global longitudinal strain, diastolic dysfunction, or left atrial enlargement.
Adults who were expected to have an ICU stay of at least three days and who had persistent hyperglycemia for up to six hours after admission, were receiving insulin, or both had a peripheral venous catheter placed and connected to a continuous
Researchers conducted an online survey of an international social media group of people with type 1 diabetes who follow a very low-carb diet (up to 30 g/d derived from fibrous vegetables and nuts).
Patients with diabetes who were taking any beta-blocker, a beta-1 selective beta-blocker, or a specific beta-blocker had significantly higher risk for all-cause mortality versus patients with diabetes who were not taking a beta-blocker.
The retrospective study at a single tertiary care referral medical center compared cost-effectiveness of care from a specialized diabetes team with care from a primary service team.
Between 2007 and 2014, more Medicare beneficiaries were newly prescribed metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, while fewer received long-acting sulfonylureas or thiazolidinediones.
After four years of follow-up, patients who had received intensive treatment during the trial had similar systolic blood pressure (BP) to those who had been on standard treatment but lower rates of cardiovascular (CV) events.
Patients with type 2 diabetes who had Roux-en-Y gastric bypass surgery maintained significant, although shrinking, improvements in HbA1c compared to those receiving lifestyle and medical management.